There are currently 25 active clinical trials seeking participants for Healthy Participants research studies. The states with the highest number of trials for Healthy Participants participants are California, Florida, Texas and Maryland.
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
NCT06814132
Recruiting
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.
Gender:
MALE
Ages:
Between 18 years and 85 years
Trial Updated:
05/09/2025
Locations: Orlando Clinical Research Center ( Site 0002), Orlando, Florida +1 locations
Conditions: Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants
Register for Updates
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
NCT06349473
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
05/06/2025
Locations: California Clinical Trials Medical Group (CCTMG), Glendale, California +7 locations
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
Register for Updates
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
NCT06908577
Recruiting
The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/05/2025
Locations: Research Site, Glendale, California +3 locations
Conditions: Healthy Participants
Register for Updates
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
NCT06713590
Recruiting
This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/30/2025
Locations: Celerion, Inc, Tempe, Arizona
Conditions: Healthy Participants
Register for Updates
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
NCT06860243
Recruiting
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Pharmacology of Miami ( Site 0002), Miami, Florida +1 locations
Conditions: Hepatic Impairment, Healthy Participants
Register for Updates
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
NCT06491550
Recruiting
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/25/2025
Locations: Research Site, Glendale, California +1 locations
Conditions: Healthy Participants
Register for Updates
A Study of LY4060874 in Healthy Participants
NCT06709820
Recruiting
The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 16 study visits.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: Fortrea, Inc., Dallas, Texas +1 locations
Conditions: Healthy Participants
Register for Updates
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
NCT06916143
Recruiting
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/17/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida +1 locations
Conditions: Healthy Participants
Register for Updates
A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults
NCT06723756
Recruiting
This study aims to assess the bioequivalence of the total systemic exposure and safety of budesonide, glycopyrronium, and formoterol (160/14.4/4.8 µg/actuation) when administered as BGF MDI HFO compared with BGF MDI HFA in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/17/2025
Locations: Research Site, Brooklyn, Maryland
Conditions: Healthy Participants
Register for Updates
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
NCT06132841
Recruiting
A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 142 years
Trial Updated:
04/17/2025
Locations: Research Site, Glendale, California +4 locations
Conditions: Healthy Participants
Register for Updates
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
NCT06564389
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy Participants, Atopic Dermatitis
Register for Updates
A Phase I Study of CDX-622
NCT06650761
Recruiting
This is a study to determine the safety of CDX-622 in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2025
Locations: Celerion, Inc., Tempe, Arizona
Conditions: Healthy Participants
Register for Updates